IPO

Lexeo IPO Drops Price for $100M Fund

Latest News Pharma

Lexeo Therapeutics Slashes IPO Price to Secure $100M Funding

3 November 2023

Anika Sharma

Lexeo Therapeutics has revealed its intention to generate substantial capital through a Nasdaq listing, despite having recently scaled back its ...

adlai therapeutics ipo, novartis abandoned cancer drug, adlai adl-001 phase 3 trial, novartis cancer drug revived by adlai, adlai ipo for colorectal cancer drug, novartis adl-001 dropped by adlai, adlai colorectal cancer drug ipo,

Latest News Pharma

Adlai revives Novartis’ abandoned cancer drug, raises $57.5M in IPO to fund phase 3 trial

29 September 2023

Anika Sharma

Adlai Nortye has solidified its financial footing, paving the way to determine the fate of its strategic investment in an ...

Acelyrin, clinical trial data, inflammatory diseases, failed trials, ulcerative colitis, phase 3 trial, IPO, stock price

Latest News Clinical Trials Pharma

Acelyrin’s lead drug flops in phase 3 trial, wiping out half of its market value

12 September 2023

Anika Sharma

Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...